Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Agios Pharm

Healthcare US AGIO

35.59USD
0.49(1.40%)

Last update at 2026-06-23T20:00:00Z

Day Range

34.6335.80
LowHigh

52 Week Range

22.2446.00
LowHigh

Fundamentals

  • Previous Close 35.10
  • Market Cap1540.39M
  • Volume744304
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-466.95501M
  • Revenue TTM54.03M
  • Revenue Per Share TTM0.93
  • Gross Profit TTM -291.85200M
  • Diluted EPS TTM-6.92

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -413.79700M 717.97M -352.08800M -231.80100M -356.51000M
Minority interest - - - - -
Net income -412.78100M 673.73M -352.08800M -74.55500M 1604.71M
Selling general administrative 180.28M 156.78M 119.90M 121.67M 121.44M
Selling and marketing expenses - - - - -
Gross profit 47.68M 32.33M 17.32M 12.54M 0.04M
Reconciled depreciation 5.18M 5.65M 6.62M 8.56M 9.24M
Ebit -472.13200M -425.73700M -391.48700M -389.04700M -378.41800M
Ebitda -466.95500M -420.08400M -384.86400M -526.75100M -385.05700M
Depreciation and amortization 5.18M 5.65M 6.62M -137.70400M -6.63900M
Non operating income net other - - - 29.39M 21.91M
Operating income -472.13200M -425.73700M -391.48700M -389.04700M -378.41800M
Other operating expenses 526.16M 462.24M 418.31M 403.29M 378.42M
Interest expense - - - 12.79M 0.84M
Tax provision -1.01600M 44.24M 0.00000M - -
Interest income 56.38M 48.08M 33.34M 12.79M 0.84M
Net interest income 56.38M 48.08M 33.34M 12.79M 0.84M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.01600M 44.24M 6.46M -157.24600M -1977.94000M
Total revenue 54.03M 36.50M 26.82M 14.24M 0.04M
Total operating expenses 519.82M 458.07M 408.81M 401.58M 378.42M
Cost of revenue 6.34M 4.17M 9.50M 1.70M 0.00071M
Total other income expense net 58.34M 1143.71M 39.40M 157.25M 21.91M
Discontinued operations - - - - 1961.22M
Net income from continuing ops -412.78100M 673.73M -352.08800M -231.80100M -356.51000M
Net income applicable to common shares - - - -231.80100M 1604.71M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1297.22M 1663.20M 937.12M 1238.72M 1437.74M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 44.13M 40.16M 35.02M 38.95M 11.82M
Total liab 104.11M 122.24M 126.10M 137.90M 145.76M
Total stockholder equity 1193.11M 1540.96M 811.02M 1100.81M 1291.97M
Deferred long term liab - - - - -
Other current liab 45.46M 46.86M 43.17M 30.35M 31.97M
Common stock 0.07M 0.07M 0.07M 0.07M 0.07M
Capital stock 0.07M 0.07M 0.07M 0.07M 0.07M
Retained earnings -561.70500M -148.92400M -822.64900M -470.56100M -238.76000M
Other liab - - - 3.28M -
Good will - - - - -
Other assets - - - 3.96M 2.90M
Cash 89.13M 76.25M 88.20M 139.26M 203.13M
Cash and equivalents - - - - -
Total current liabilities 82.21M 81.16M 67.95M 62.63M 59.83M
Current deferred revenue - -16.78100M - - -
Net debt -27.10800M -19.25900M -16.20900M -53.60000M -106.03200M
Short term debt 18.39M 16.78M 15.01M 13.66M 11.16M
Short long term debt - - - - -
Short long term debt total 62.02M 56.99M 72.00M 85.66M 97.09M
Other stockholder equity 1752.55M 1691.33M 1634.04M 1583.84M 1531.86M
Property plant equipment - - - 22.99M 28.92M
Total current assets 942.05M 965.60M 833.84M 832.77M 1064.23M
Long term investments 310.01M 638.32M 29.43M 313.87M 266.38M
Net tangible assets - - - 1100.81M 1291.97M
Short term investments 765.29M 817.46M 688.72M 643.86M 816.89M
Net receivables 10.58M 4.11M 2.81M 2.21M 4.38M
Long term debt - - - - -
Inventory 32.92M 27.62M 19.08M 8.49M 16.19M
Accounts payable 18.36M 16.64M 9.78M 18.62M 16.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.19M -1.51800M -0.44100M -12.53500M -1.19800M
Additional paid in capital - - - - -
Common stock total equity - - - 0.07M 0.07M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -470.56100M -238.76000M
Treasury stock - - - -802.48600M -802.48600M
Accumulated amortization - - - - -
Non currrent assets other 3.93M 4.72M 4.06M 3.96M 2.90M
Deferred long term asset charges - - - - -
Non current assets total 355.17M 697.60M 103.28M 405.95M 373.50M
Capital lease obligations 40.21M 56.99M 72.00M 85.66M 97.09M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 391.50M 363.44M 239.57M 243.26M -548.41700M
Change to liabilities - - - 4.82M 1.93M
Total cashflows from investing activities 377.18M 363.44M 239.57M 243.26M 1248.78M
Net borrowings - 0.00000M 0.00000M -0.33100M -0.57800M
Total cash from financing activities 8.68M 14.44M 5.43M 2.35M -765.76800M
Change to operating activities - - - -9.17100M -34.30700M
Net income -412.78100M 673.73M -352.08800M -231.80100M -356.51000M
Change in cash 12.88M -11.95800M -51.05400M -63.86700M 75.69M
Begin period cash flow 76.25M 88.20M 139.26M 203.13M 127.44M
End period cash flow 89.13M 76.25M 88.20M 139.26M 203.13M
Total cash from operating activities -372.97700M -389.84100M -296.06200M -309.47800M -407.32000M
Issuance of capital stock - - - - 0.00000M
Depreciation 5.18M 5.65M 6.62M 8.56M 9.24M
Other cashflows from investing activities -10.00000M 1089.14M -16.17500M 132.75M 1802.94M
Dividends paid - - - - -
Change to inventory -5.30400M -8.54000M -10.58400M -8.49200M -8.49200M
Change to account receivables -6.46800M -1.29900M -0.60400M -2.20600M -4.37800M
Sale purchase of stock - - 0.00000M 2.68M -802.48600M
Other cashflows from financing activities 8.68M 14.44M 5.43M 2.68M 37.30M
Change to netincome - - - 49.25M -39.71400M
Capital expenditures 4.32M 1.69M 1.00M 4.88M 5.74M
Change receivables - - - -2.20600M -
Cash flows other operating - - - -360.21600M -385.72400M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -63.86700M 75.69M
Change in working capital -33.04200M -19.76800M -19.05700M -16.43300M -36.82200M
Stock based compensation 52.55M 42.85M 44.77M 49.30M 53.51M
Other non cash items 15.12M -1092.29800M 23.69M -119.10400M 9.54M
Free cash flow -377.29300M -391.52600M -297.06100M -314.35900M -413.06100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AGIO
Agios Pharm		 0.49 1.40% 35.59 - 2.47 28.51 1.33 14.28 -2.3282
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Agios Pharm

88 Sidney Street, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Dr. Bruce D. Car DACVP, Ph.D. Consultant 1961
Dr. Sarah Gheuens M.D., Ph.D. Chief Medical Officer and Head of R&D 1980
Ms. Richa Poddar Chief Commercial Officer 1982
Mr. Brian M. Goff M.B.A. CEO & Director 1969
Dr. Lewis Clayton Cantley Ph.D. Co-Founder & Member of Scientific Advisory Board 1949
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. Co-Founder & Member of Scientific Advisory Board 1946
Dr. Craig B. Thompson M.D. Co-Founder & Chairman of Scientific Advisory Board 1953
Dr. Shin-San Su Ph.D. Co-Founder & Member of Scientific Advisory Board 1956
Ms. Cecilia Jones Chief Financial Officer 1975
Mr. T. J. Washburn Jr. Principal Accounting Officer 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.